| PRODUCTS |
|
| RESOURCES & SUPPORT |
|
|
 |
Please contact your local IMGENEX distributor for pricing on these products. For a list of distributors, click here or go to www.imgenex.com/distributors.php
| Browse antibodies alphabetically |
|
|
| Click to go directly to our Product list |
| Antibodies from IMGENEX: Toll-like Receptors |
|
The GateKeepers of
Innate Immunity |
|
Innate
immunity as the first line of defense The innate immune
system is an ancient host defense mechanism found in almost every multicellular
organism from plants to humans. In invertebrates it is the sole mechanism of
defense against pathogens but in higher vertebrates constitutes the first line
of defense. The role of the innate immune system is not an insignificant one;
not only must it discriminate between self and non-self as well as distinguish
between pathogenic and non-pathogenic microbes, it also plays an important role
in triggering and optimizing the adaptive immune response. This remarkable
system allows an immediate non-specific response against microorganisms whereas
the adaptive immunity mounts a specific response against the invading pathogen
during the late phase of the infection.
|
|
|
|
|
|
 |
|
Request a poster
now!
|
|
Pattern Recognition Receptors
The
cornerstone of the innate immune system is comprised of germline-encoded
receptors referred to as pattern-recognition receptors (PRRs), to which
the Toll-like receptors belong. These PRRs are activated upon
recognition of “Pathogen-Associated Molecular Patterns” or PAMPs.
PAMPs are molecular patterns shared by large groups of pathogens not
usually present in the host.
1. Molecular patterns system must be shared by large groups of
pathogens and thus must represent general patterns rather then specific
structures.
2. They must be conserved products of microbial metabolism which are
not subject to antigenic variability. Although the immune system
selects against these patterns, pathogens cannot "change" them because
they are essential for the survival or pathogenicity of the
microorganisms. Any attempts to change them could be lethal to the
microbe or render it nonpathogenic.
3. The recognized structures must be absolutely distinct from
self-antigens. The major consequence of this requirement is the ability
of the innate immune system to discriminate between self and non-self.
Characterized PAMPS include cell wall constituents such as
lipopolysaccharide (LPS), peptidoglycan (PGN), lipoteichoic acid (LTA),
or lipoarabinomannan (LAM), but also include single or double and
stranded RNA, as well as unmethylated CpG DNA.
Overview of Toll-like Receptors
The TLRs owe their name to a closely related
receptor called Toll, first identified in Drosophila. The first member of the
Toll family was identified in Drosophila in 1988 during a screen for embryonic
polarity genes. In Drosophila, Toll receptors cause an induction of innate
immune responses by first linking to an adaptor tube, which is a functional
homolog of mammalian MyD88. This tube binds to kinase Pelle, a homologue of
IRAK, and after a cascade of reactions leads to transcription of genes that
modulate and mediate activation of antimicrobial pathways that directly kill the
pathogen.
Toll and its mammalian homologs are type I transmembrane
proteins characterized by an extracellular leucine-rich domain and a cytoplasmic
domain referred to as Toll/IL-1R domain or TIR domain because of its homology to
the cytoplasmic domain of the mammalian interleukin 1 receptor (IL-1R). Upon
binding of the extracellular ligand recognition domain to specific PAMPs,
changes in the intracellular domain result in initiation of signaling events
including translocation of transcription factors, cytokine modulation, and
interferon-stimulated gene regulation leading to inflammatory responses and/or
release of antimicrobial agents.
The first characterized member of the
mammalian family of TLRs was TLR4 which was shown to trigger the
pro-inflammatory NF-kB pathway upon binding to LPS. The completion of the human
genome project led to the identification of numerous putative TLRs in the
genome. These TLRs differ from each other in ligand specificities, expression
patterns, and target genes they induce.
At least 11 TLRs have been
identified in humans and 13 in mice. While they are expressed predominantly in
antigen processing and presentation cells such as macrophages, neutrophils, and
dendritic cells, TLR expression is not restricted to these cell types. Although
research is ongoing, TLR expression—at least at the mRNA level—appears to be
detectable in a wide range of tissues including adrenal gland, liver, lung,
spinal cord, spleen, testis, thymus, and trachea suggesting that subsets of TLRs
are expressed in the majority of cells in the body.
TLR Signaling
Stimulation of TLRs by pathogens leads to
expression of several genes involved in immune responses through a number of
signaling pathways. Activated pathways include the NF-kB pathway (IkBa
phosphorylation, translocation of NF-kB p65 to the nucleus), mitogen activated
protein kinases p38, Jun-N-terminal kinase (JNK), and the interferon pathway.
While TLR-mediated signaling pathways are still being elucidated, a
number of specific molecules are known to be involved. These include adapter
molecules such as MyD88, MyD88 adapter-like (Mal), also known as Toll/IL-1R
(TIR) domain containing adaptor protein (TIRAP), and TIR domain-containing
adapter inducing interferon (TRIF), also known as TICAM1. Other key signaling
proteins include IL-1 receptor associated kinases (IRAKs) such as IRAK1, 2, and
4, transforming growth factor kinase (TAK-1), IkB kinases (IKKs), and TRAFs (TNF
receptor associated factors).
Summary of Toll-like Receptors & their Ligands
|
Receptor |
Bacteria |
Viruses |
Fungi |
Parasites |
Small/Synthetic Molecules |
Endogenous Ligands |
|
TLR1/TLR2 |
Triacyl lipopeptides lipoarabinomannan
(LAM) from mycobacterium
|
|
Yeast/ Zymosan
|
Glycosylphosphatidyl inositol linked
proteins,
T. cruzi
|
|
|
|
TLR2/TLR2 (?) |
Published literature suggests the
existence of TLR2 homo-dimers, though specific ligands have yet to
be identified. |
|
TLR2/TLR6 |
diacyl
lipopeptides, LTA peptidoglycan
|
|
Yeast/ Zymosan
|
Glycosylphosphatidyl inositol linked
proteins,
T. cruzi
|
|
|
|
TLR3 |
|
dsRNA |
|
|
|
|
|
TLR4 |
LPS |
|
|
|
(Mouse TLR4),
Taxol |
Hsp60, Hsp70?, Hyaluronic Acid?
Heparan Sulfate? Fibrinogen?
|
|
TLR5 |
Flagellin |
|
|
|
|
|
|
TLR7 |
|
ssRNA |
|
|
Imidazoquinolines (Mouse TLR7),
Loxoribine
|
|
|
TLR8 |
ssRNA |
|
|
|
(Human TLR8) Imidazoquinolines |
|
|
TLR9 |
Bacterial CpG
|
Viral CpG |
|
|
|
|
|
TLR10 |
Unknown ligand(s) |
|
TLR11 |
(Mouse TLR11) Uropathogenic Bacteria
|
|
|
(Mouse TLR11)
T. gondii profilin,
apicomplexan profilins? |
|
|
|
TLR12 |
Unknown ligand(s) |
|
TLR13 |
Unknown ligand(s)
|
|
|
|
|
|
Found 124, displaying 1 to 50 |
Next >> |
|
|
|
Format |
Species |
Clone |
Appl. |
Unit |
Price |
MSDS |
| IMG-90190-1 |
EGFR (Ser1070) |
Purified, Peptide Affinity |
H, M, R |
N/A |
IHC, WB |
50 µg |
N/A |
|
| IMG-567 |
TLR Antibody Sampler Kit |
Purified |
M |
N/A |
|
5 tubes |
N/A |
|
| IMG-568 |
TLR downstream Ab sampler kit |
Kit |
|
N/A |
|
7 tubes |
N/A |
|
| IMG-500 |
TLR sampler kit |
Purified |
M |
N/A |
|
0.025 mg each |
N/A |
|
| IMG-5012 |
TLR1/CD281 |
Purified |
H, M, R |
N/A |
Flow (Cell Surface), Flow (Intracellular), WB |
0.1 mg |
N/A |
|
| IMG-5629-1 |
TLR1/CD281 |
Purified |
H, M |
N/A |
WB |
0.05 mg |
N/A |
|
| IMG-5629-2 |
TLR1/CD281 |
Purified |
H, M |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-386A |
TLR10/CD290 |
Purified |
H |
158C1114 |
Flow (Cell Surface), Flow (Intracellular), WB |
0.1 mg |
N/A |
|
| IMG-5255A |
TLR10/CD290 |
Purified |
M, R |
N/A |
ELISA, WB |
0.1 mg |
N/A |
|
| IMG-386D |
TLR10/CD290 |
PE |
H |
158C1114 |
Flow (Cell Surface), Flow (Intracellular) |
0.1 mg |
N/A |
|
| IMG-386C |
TLR10/CD290 |
FITC |
H |
158C1114 |
Flow (Cell Surface), Flow (Intracellular) |
0.1 mg |
N/A |
|
| IMG-5630-1 |
TLR10/CD290 (IN) |
Purified |
H |
N/A |
WB |
0.05 mg |
N/A |
|
| IMG-5630-2 |
TLR10/CD290 (IN) |
Purified |
H |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-5104A |
TLR11 |
Purified |
M |
N/A |
Flow (Intracellular), WB |
0.1 mg |
N/A |
|
| IMG-5650-1 |
TLR11 (IN) |
Purified |
M |
N/A |
IF/ICC, WB |
0.05 mg |
N/A |
|
| IMG-5650-2 |
TLR11 (IN) |
Purified |
M |
N/A |
IF/ICC, WB |
0.1 mg |
N/A |
|
| IMG-5034 |
TLR12 |
Purified |
M |
N/A |
Flow (Intracellular), WB |
0.1 mg |
N/A |
|
| IMG-5037 |
TLR12 |
Ascites |
M |
15F1215 |
WB |
0.2 mL |
N/A |
|
| IMX-5167 |
TLR13 |
Sera |
M, R |
N/A |
Peptide ELISA* |
0.1 mL |
N/A |
|
| IMX-5168 |
TLR13 |
Sera |
M, R |
N/A |
Peptide ELISA* |
0.1 mL |
N/A |
|
| IMX-5169 |
TLR13 |
Sera |
M, R |
N/A |
Peptide ELISA* |
0.1 mL |
N/A |
|
| IMX-5170 |
TLR13 |
Sera |
M, R |
N/A |
Peptide ELISA* |
0.1 mL |
N/A |
|
| ABU009 |
TLR13 Antibody Bundle |
Sera |
M |
N/A |
ELISA |
4 tubes |
N/A |
|
| IMG-5628 |
TLR1; Discontinued: please see IMG-5012 |
Purified |
H |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-319 |
TLR2/CD282 |
Ascites |
H |
1030A5.138 |
Flow (Cell Surface), Flow (Intracellular), IHC (paraffin), WB |
0.2 mL |
N/A |
|
| IMG-410A |
TLR2/CD282 |
Purified |
H, M |
N/A |
IHC (paraffin), WB |
0.1 mg |
N/A |
|
| IMG-416A |
TLR2/CD282 |
Purified |
D, H |
TL2.1 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC, IP |
0.1 mg |
N/A |
|
| IMG-416C |
TLR2/CD282 |
FITC |
D, H |
TL2.1 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC |
0.1 mg |
N/A |
|
| IMG-416D |
TLR2/CD282 |
PE |
H |
TL2.1 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC |
0.1 mg |
N/A |
|
| IMG-416E |
TLR2/CD282 |
Azide-Free |
H |
TL2.1 |
FA (Neutralization), Flow (Cell Surface), Flow (Intracellular), IF/ICC, IP |
0.1 mg |
N/A |
|
| IMG-526 |
TLR2/CD282 |
Purified |
H, M |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-545 |
TLR2/CD282 |
Purified |
C, H, M, R |
N/A |
WB |
0.2 mL |
N/A |
|
| IMG-662 |
TLR2/CD282 |
Purified |
M |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-416B |
TLR2/CD282 |
Biotin |
H |
TL2.1 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC, IP |
0.1 mg |
N/A |
|
| IMG-410E |
TLR2/CD282 |
Azide-Free |
H, M |
N/A |
WB |
0.1 mg |
N/A |
|
| IMG-5651-1 |
TLR2/CD282 |
Purified |
H, M |
N/A |
IHC (paraffin), WB |
0.05 mg |
N/A |
|
| IMG-5651-2 |
TLR2/CD282 |
Purified |
H, M |
N/A |
IHC (paraffin), WB |
0.1 mg |
N/A |
|
| IMG-315A |
TLR3/CD283 |
Purified |
H |
40C1285.6 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC, IHC (paraffin), IP, WB |
0.1 mg |
N/A |
|
| IMG-315C |
TLR3/CD283 |
FITC |
H |
40C1285.6 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC |
0.1 mg |
N/A |
|
| IMG-315D |
TLR3/CD283 |
PE |
H |
40C1285.6 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC |
0.1 mg |
N/A |
|
| IMG-516 |
TLR3/CD283 |
Purified |
M |
N/A |
Flow (Cell Surface), Flow (Intracellular), IHC (frozen), IHC (paraffin), WB |
0.1 mg |
N/A |
|
| IMG-315B |
TLR3/CD283 |
Biotin |
H |
40C1285.6 |
ELISA, Flow (Cell Surface), Flow (Intracellular), IHC (paraffin) |
0.1 mg |
N/A |
|
| IMG-315F |
TLR3/CD283 |
Atto 488 |
H |
40C1285.6 |
Flow (Cell Surface), Flow (Intracellular), IF/ICC |
0.1 mg |
N/A |
|
| DDX0474 |
TLR3/CD283 |
Purified |
D, H, M, R |
713E4.06 |
Flow (Intracellular), IHC (paraffin) |
0.1 mg |
N/A |
|
| DDX0474A488 |
TLR3/CD283 |
Alexa 488 |
D, H, M, R |
713E4.06 |
Flow (Intracellular), IHC (paraffin) |
0.1 mg |
N/A |
|
| DDX0474A546 |
TLR3/CD283 |
Alexa 546 |
D, H, M, R |
713E4.06 |
Flow (Intracellular), IHC (paraffin) |
0.1 mg |
N/A |
|
| DDX0474B |
TLR3/CD283 |
Biotin |
D, H, M, R |
713E4.06 |
Flow (Intracellular), IHC (paraffin) |
0.1 mg |
N/A |
|
| DDX0475 |
TLR3/CD283 |
Purified |
H, M, R |
716G10.15 |
Flow (Intracellular), IHC (frozen) |
0.1 mg |
N/A |
|
| DDX0475A488 |
TLR3/CD283 |
Alexa 488 |
H, M, R |
716G10.15 |
Flow (Intracellular), IHC (frozen) |
0.1 mg |
N/A |
|
| DDX0475A546 |
TLR3/CD283 |
Alexa 546 |
H, M, R |
716G10.15 |
IHC (frozen) |
0.1 mg |
N/A |
|
|
|
|
 |
| PRODUCT SEARCH |
|
| INTERACTIVE PATHWAYS |
|
|
DOWNLOAD POSTERS & LITERATURE

Click Here
|
|
|
|